Alcanza Clinical Research Receives 2025 HCPEA Impact Award

The award recognizes Alcanza's mission-driven approach to advancing inclusive, community-based clinical research.

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

Alcanza Clinical Research, a leading network of fully owned, community-based clinical research sites, has been honored with the 2025 HCPEA Impact Award by the Healthcare Private Equity Association. The award recognizes Alcanza's mission-driven approach to expanding access to clinical research and delivering life-changing outcomes, particularly among historically underrepresented populations.

Why it matters

The HCPEA Impact Award highlights the vital role private equity plays in strengthening the healthcare system through measurable progress across critical areas, including access to care, quality and outcomes, innovation, efficiency, workforce engagement, and health equity. Alcanza's recognition demonstrates how thoughtful investment, strong leadership, and a clear mission can drive meaningful improvements in these areas.

The details

Alcanza, meaning 'to reach' in Spanish, is a leading network of fully owned, community-based clinical research sites designed to meet patients where they are. Through its purpose-built facilities and emphasis on research quality and rapid study startup, Alcanza enables sponsors, clinical research organizations, and healthcare providers to conduct multi-phase trials efficiently while expanding participation among historically underrepresented populations.

  • Alcanza was formed in 2021 via the initial acquisition of three high-performing clinical research brands by Martis Capital.
  • Alcanza has significantly scaled its impact over the past few years, growing the number of active studies more than fourfold and achieving participant diversity levels that remain uncommon across the industry.

The players

Alcanza Clinical Research

A leading network of fully owned, community-based clinical research sites designed to meet patients where they are and expand access to clinical research, particularly among historically underrepresented populations.

Martis Capital

The private equity firm that helped form Alcanza in 2021 through the initial acquisition of three high-performing clinical research brands.

Carlos Orantes

The CEO of Alcanza Clinical Research.

Mario Moreno

A Partner at Martis Capital and a member of the Alcanza Board of Directors.

Healthcare Private Equity Association (HCPEA)

A nonprofit trade association focused on convening and supporting the healthcare investment community, which awarded Alcanza with the 2025 HCPEA Impact Award.

Got photos? Submit your photos here. ›

What they’re saying

“Receiving the HCPEA Impact Award is an incredible honor and a reflection of the passion our teams bring to expanding access to clinical research every day. At Alcanza, we believe medical progress depends on research that truly reflects the communities it aims to serve. This recognition reinforces our commitment to inclusive, compassionate research that delivers life-changing outcomes.”

— Carlos Orantes, CEO of Alcanza Clinical Research

“Alcanza embodies exactly what the HCPEA Impact Award was created to recognize. The organization demonstrates how thoughtful investment, strong leadership, and a clear mission can drive meaningful improvements in health equity, research quality, and innovation. We are proud to support Alcanza as it continues to redefine what inclusive clinical research can achieve.”

— Mario Moreno, Partner at Martis Capital and Alcanza Board Member

The takeaway

Alcanza's recognition with the HCPEA Impact Award highlights how private equity investment, strong leadership, and a mission-driven approach can drive meaningful progress in healthcare, particularly in expanding access to clinical research and improving health equity.